GLU-ASN-GLY-LEU-PRO-VAL-HIS-LEU-ASP-GLN-SER-ILE-PHE-ARG-ARG
| 中文名稱 | GLU-ASN-GLY-LEU-PRO-VAL-HIS-LEU-ASP-GLN-SER-ILE-PHE-ARG-ARG |
|---|---|
| 中文同義詞 | (2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S,15Z,17S,18Z,20S)-20-((Z)-((S)-2-((Z)-((S))-2-((Z)-((S)-2-((Z)-(((S)-1-((S)-2-((Z)-(2-((Z)-((S)-2-((Z)-((S)-2-氨基-4-羧基-1-羥基丁烯)氨基)-1,4-二羥基-4-亞氨基丁烯)氨基)-1-羥基乙叉)氨基)-4-甲基戊?；?吡咯烷-2-基)(羥基)亞甲基)氨基)-1-羥基-3-甲基丁烯)氨基)-1-羥基-3-(1H-咪唑-5-基)亞丙基)氨基)-1-羥基-4-甲基亞戊基)氨基)-8-芐基-11-((S)-仲丁基)-2,5-雙;化合物 ANGIOGENIN (108-122) |
| 英文名稱 | ANGIOGENIN (108-122) |
| 英文同義詞 | ANGIOGENIN (108-122);H-GLU-ASN-GLY-LEU-PRO-VAL-HIS-LEU-ASP-GLN-SER-ILE-PHE-ARG-ARG-OH;GLU-ASN-GLY-LEU-PRO-VAL-HIS-LEU-ASP-GLN-SER-ILE-PHE-ARG-ARG;angiogenin fragment 108-122;Angiogenin (108-122) H-Glu-Asn-Gly-Leu-Pro-Val-His-Leu-Asp-Gln-Ser-Ile-Phe-Arg-Arg-OH;L-Arginine, L-α-glutamyl-L-asparaginylglycyl-L-leucyl-L-prolyl-L-valyl-L-histidyl-L-leucyl-L-α-aspartyl-L-glutaminyl-L-seryl-L-isoleucyl-L-phenylalanyl-L-arginyl-;1:PN:WO2013051767 SEQID:1 claimed protein;ENGLPVHLDQSIFRR |
| CAS號 | 112173-49-6 |
| 分子式 | C78H125N25O23 |
| 分子量 | 1780.98 |
| EINECS號 | |
| 相關(guān)類別 | |
| Mol文件 | 112173-49-6.mol |
| 結(jié)構(gòu)式 |  |
GLU-ASN-GLY-LEU-PRO-VAL-HIS-LEU-ASP-GLN-SER-ILE-PHE-ARG-ARG 性質(zhì)
| 密度 | 1.49±0.1 g/cm3(Predicted) |
|---|---|
| 儲(chǔ)存條件 | Keep in dark place,Sealed in dry,2-8°C |
| 酸度系數(shù)(pKa) | 3.31±0.10(Predicted) |
| 序列 | Glu-Asn-Gly-Leu-Pro-Val-His-Leu-Asp-Gln-Ser-Ile-Phe-Arg-Arg |
Angiogenin (108-122) 是一種血管生成素肽。
Angiogenin (108-122) effects on the ribonucleolytic activity of angiogenin using tRNA as substrate with 39% inhibition. Angiogenin (108-122) acts as a therapeutic agent for the prophylaxis and/or treatment of cancer, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, an autoimmune disease, or a heart and vascular disease.